Registered outcomes16

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 16 of 16

List	Outcome	Time frame	Description
Primary	Percentage of time of glucose levels spent in the target range (3.9-10.0 mmol/L).	18 days
Secondary	Percentage of time of glucose levels spent between 3.9-7.8 mmol/L.	18 days
Secondary	Percentage of time of glucose levels spent between 3.0-3.9 mmol/L.	18 days
Secondary	Percentage of time of glucose levels spent between 10.0-13.9 mmol/L.	18 days
Secondary	Mean glucose levels.	18 days
Secondary	Standard deviation of glucose levels.	18 days
Secondary	Coefficient of variance of glucose levels.	18 days
Secondary	Total pramlintide delivery (overall, basal, and bolus).	18 days
Secondary	Total insulin delivery (overall, basal, and bolus).	18 days
Secondary	Mean score on the Type 1 Diabetes Distress Scale (T1DDS) excluding the physician subscale.	18 days	A scale from 1-6 indicating overall diabetes distress. Higher scores indicate higher levels of diabetes distress. Any total subscale score of \>2.0 is considered clinically significant.
Secondary	Mean score on the Hypoglycemia Fear Survey - II (Worry Subscale) (HSF2).	18 days	A scale from 1-5 with higher scores indicating a greater fear of hypoglycemia.
Secondary	Mean score on the INSPIRE questionnaire for adults (INSPIRE).	18 days	A scale from 1-5 with higher scores reflecting more favorable opinions about using Automated Insulin Delivery (AID).
Secondary	Mean score on selected items from The Diabetes Bowel Symptoms Questionnaire (DBSQ).	18 days	A 1-5 scale with higher values reflecting a greater quantity and severity of diabetes bowel symptoms.
Secondary	Mean score on a Treatment Satisfaction Questionnaire (TSQ) taken from Marrero et al.	18 days	A 1-6 scale with higher values indicating more satisfaction with treatment.
Secondary	Thematic interview analysis	18 days	Semi-structured interviews will be carried out after every intervention. We will analyze their qualitative content.
Other	Safety Endpoints	18 days	Number of adverse events, including gastrointestinal symptoms.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT06046417/registered

API reference For AI assistants